H1 secures $40 million investment from CVS Health Ventures
CEO Ariel Katz argues that while generative AI can replicate workflow software, it cannot easily replicate the company’s core business of aggregating detailed physician data.
Healthcare data platform H1 has secured a $40 million investment led by CVS Health Ventures, the corporate venture capital arm of CVS/Aetna. The funding round underscores the continued appetite for profitable, non-AI software companies, even as traditional venture capitalists increasingly prioritise artificial intelligence startups at elevated valuations.
CEO Ariel Katz stated that the company was not actively seeking capital, having achieved cash flow and EBITDA profitability in the previous year. H1 forecasts growth of over 40 per cent for the current year. However, Katz described the partnership with one of the world’s largest healthcare conglomerates as a strategic opportunity that was difficult to decline, given the value of H1’s global physician data aggregation.
Katz distinguished H1’s business model from typical software-as-a-service (SaaS) providers. He argued that while AI models, such as Anthropic’s Claude, could replicate workflow software, they cannot easily replicate the core data provision business. H1 specialises in selling detailed information about doctors to pharmaceutical companies, hospital systems, and health insurers.
The CEO suggested that AI model makers may become customers rather than competitors, citing the high value of the structured physician data H1 provides. This perspective positions the company as a potential data supplier for the next generation of AI tools, rather than a victim of automation.
H1, a nine-year-old platform, was previously valued at $750 million when it raised $100 million in funding led by Altimeter Capital in November 2021. Following the valuation correction in 2022, the company focused on operational efficiency and profitability. It has also expanded its market position through the acquisition of smaller competitors and complementary businesses.
The investment highlights a divergence in the current venture capital landscape. While many pre-AI era startups face limited investor interest, H1’s proven profitability and specialised data assets have attracted significant corporate backing. The deal signals that established SaaS companies with strong fundamentals and unique data moats remain viable targets for strategic investment.
